胶质母细胞瘤基于免疫疗法的现状

Current State of Immune-Based Therapies for Glioblastoma.

作者信息

Lim Michael, Weller Michael, Chiocca E Antonio

机构信息

From The Johns Hopkins University, Baltimore, MD; University Hospital Zurich, Zurich, Switzerland; Institute for the Neurosciences at the Brigham and Women's/Faulkner Hospital, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA; The University of Chicago, Chicago, IL.

出版信息

Am Soc Clin Oncol Educ Book. 2016;35:e132-9. doi: 10.1200/EDBK_159084.

DOI:10.1200/EDBK_159084

PMID:27249715

Abstract

Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immunosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be reviewed.

摘要

胶质母细胞瘤是最具侵袭性的实体瘤之一，尽管有手术、放疗和化疗等治疗选择，但其预后仍然严峻。需要新的方法来提高生存率。免疫疗法已被证明对黑色素瘤、肺癌和肾癌有效，现在是胶质母细胞瘤的研究重点。在本文中，将讨论胶质母细胞瘤介导的免疫抑制，并综述两种令人兴奋的免疫方法，即检查点抑制剂和基于病毒的疗法。